COVID-19 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Coronaviruses (CoVs) are a family of RNA viruses grouped into three categories: α-CoVs, β-CoVs, and γ-CoVs. SARS-CoV-2, similar to MERS-CoV and SARS-CoV, belongs to the β-CoV group. These viruses have a large, enveloped, single-stranded RNA genome and encode four key structural proteins: spike (S), nucleocapsid (N), membrane (M), and envelope (E) proteins. Although coronaviruses primarily infect birds and mammals, some have jumped to humans, causing zoonotic diseases. SARS-CoV-2 primarily spreads through respiratory droplets and may be transmitted through eye contact or the fecal-oral route. COVID-19 severity varies, from mild cold-like symptoms to severe respiratory illness. Common symptoms include fever, cough, fatigue, and shortness of breath, with less frequent reports of headache, sore throat, hemoptysis, and diarrhea. FDA-approved treatments for COVID-19 include the IV antiviral Veklury (remdesivir), immune modulators Olumiant (baricitinib) and Actemra (tocilizumab), and the oral antiviral Paxlovid (nirmatrelvir and ritonavir).
Thelansis’s “COVID-19 Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential COVID-19 treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of COVID-19 across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
COVID-19 Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment